About Vapogenix
Vapogenix is a clinical stage company developing a new class of topical, non-opioid analgesics to alleviate pain. While most pain is localized, most pain medications are administered orally, which often results in systemic side effects. We are focused on treating pain locally – at its source. Our products are volatile anesthetics formulated for topical application; currently unformulated volatile anesthetics are approved for use only as general anesthetics. Our lead product is a topical analgesic, has recently completed a Phase II clinical trial for treating wound pain. A second product, which has completed its first clinical trial, is a rapidly acting topical analgesic for use on intact skin, to alleviate acute procedural pain such as venipuncture, venous cannulation and minor dermatological procedures. Our third topical product focuses on treating localized inflammatory pain.
Vapogenix was founded by Dr. Allen Burton, Dr. Phillip Phan and Ms. Danguole Altman. Dr. Burton and Dr. Phan were searching for non-narcotic pain medications to alleviate the chronic neuropathic pain experienced by many of their patients - cancer survivors. Their discovery, that formulated volatile anesthetics can successfully alleviate localized pain, forms the basis of our technology. Our plans are to build a suite of products for the treatment of various localized painful conditions.
Vapogenix is a clinical stage company developing a new class of topical, non-opioid analgesics to alleviate pain. While most pain is localized, most pain medications are administered orally, which often results in systemic side effects. We are focused on treating pain locally – at its source. Our products are volatile anesthetics formulated for topical application; currently unformulated volatile anesthetics are approved for use only as general anesthetics. Our lead product is a topical analgesic, has recently completed a Phase II clinical trial for treating wound pain. A second product, which has completed its first clinical trial, is a rapidly acting topical analgesic for use on intact skin, to alleviate acute procedural pain such as venipuncture, venous cannulation and minor dermatological procedures. Our third topical product focuses on treating localized inflammatory pain.
Vapogenix was founded by Dr. Allen Burton, Dr. Phillip Phan and Ms. Danguole Altman. Dr. Burton and Dr. Phan were searching for non-narcotic pain medications to alleviate the chronic neuropathic pain experienced by many of their patients - cancer survivors. Their discovery, that formulated volatile anesthetics can successfully alleviate localized pain, forms the basis of our technology. Our plans are to build a suite of products for the treatment of various localized painful conditions.